Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone

Pawan Kumar, Qinghong Gao, Yu Ning, Zhuo Wang, Paul H. Krebsbach and Peter J. Polverini
Pawan Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qinghong Gao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Ning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhuo Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul H. Krebsbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Polverini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-0287 Published July 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    As2O3 enhances radiation-induced endothelial cell and tumor cell death while protecting osteoblasts. Endothelial cells (HDMEC, 5 × 103), tumor cells (OSCC-3, 3 × 103), and osteoblasts (NHOst, 5 × 103) were plated in 96-well plates at 37°C and cultured overnight. A, cells were treated with 0.5, 1, 2.5, 5, 10, and 20 μmol/L doses of As2O3. B, cells were treated with As2O3 (AS, 5 μmol/L) followed by radiation treatment (IR, 7.5 Gy). After 72 h of culture, 10 μL of WST/ECS solution (BioVision) was added into each well and these cells were further incubated at 37°C for 2 to 4 h (2 h for OSCC-3 and 4 h for HDMEC and NHOst). The reaction was stopped by adding 1% SDS and plates were read on a microplate reader at a wavelength of 440 nm. The percentage of survival was calculated by adjusting the control group (no treatment, NT) to 100%. Each test group was run in eight wells and each assay was repeated at least thrice. *, P < 0.05, significant difference as compared with the control group. C, HDMEC, OSCC-3, and NHOst cells were cultured in 6 cm dishes. After 24 h, cells were treated with As2O3 (AS, 5 μmol/L) for 1 h and then exposed to a single dose of γ-irradiation (7.5 Gy) and cultured for an additional 72 h. Upon completion of incubation, cells were harvested and the percentage of apoptotic cells was evaluated by the TUNEL assay according to the manufacturer's instructions (Sigma). *, P < 0.05, significant difference as compared with the control group.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    As2O3 enhances radiation-induced inhibition of endothelial cell tube formation. The Matrigel in vitro HDMEC tube formation assay was done in eight-well chamber slides. A and B, endothelial cells cultured on top of Matrigel were treated with VEGF and different doses of As2O3 (AS). A, photomicrographs of representative assays for no-treatment (NT), VEGF, VEGF + As2O3 (AS) 2.5 μmol/L, VEGF + AS 5 μmol/L, VEGF + AS 10 μmol/L, and VEGF + AS 20 μmol/L. B, quantitative data for HDMEC tube formation from three independent experiments (points, mean; bars, SE). C, HDMECs were cultured on top of Matrigel and were treated with VEGF alone or with radiation (7.5 Gy) and/or As2O3. *, P < 0.05, significant increase as compared with the no-treatment (NT) group; **, P < 0.05, significant decrease as compared with the VEGF group.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    As2O3 enhances radiation-induced inhibition of tumor cell colony formation. The tumor cell colony formation assay was done in low–melting point agarose in 24-well plates. A and B, tumor cells (OSCC-3) were treated with different concentrations of As2O3 (2.5, 5, 10, and 20 μmol/L) and cultured for 14 d. C and D, tumor cells (OSCC-3 and UM-SCC-74A) were treated with As2O3 or radiation, or a combination of both and cultured for 14 d. The number of colonies formed in each test group was counted at low-power field (×50). The percentage of colonies formed was calculated by adjusting the control group (no treatment, NT) to 100%. *, P < 0.05, significant difference as compared with the no-treatment (NT) group; **, P < 0.05, significant difference as compared with As2O3 or radiation treatment alone.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    As2O3 and radiation treatment significantly inhibit tumor growth in vivo. Gelfoam carrier (3 × 3 mm2) seeded with 2 × 106 BMSCs each were implanted into the flanks of 6-week-old SCID mice (eight animals/group). After 2 wk, tumor cells (OSCC-3 or UM-SCC-74A, 1 × 106) and HDMECs (1 × 106) were mixed with 100 μL of Matrigel and these cells were implanted into the flanks of SCID mice adjacent to the bone ossicles. Tumors were allowed to grow and vascularize for 8 d and then three doses of As2O3 (2 or 5 mg/kg, days 8, 12, and 15) and three fractionated doses of ionizing radiation (7.5 Gy × 3, days 9, 13, and 16) were administered. Tumor volume measurements began on day 1 (tumor inoculation) and continued twice a week until the end of the study. A, representative photomicrograph of tumor and bone ossicle growing side by side in a SCID mouse. B, cut tumors (OSCC-3) from no-treatment (NT), As2O3 5 mg/kg (AS 5 mg/kg), radiation treatment (IR), and As2O3 5 mg/kg + radiation treatment (AS 5 mg/kg + IR) groups. Dotted circle and arrow, areas of necrosis. C and D, tumor progression curves for OSCC-3 and UM-SCC-74A tumors treated with As2O3 (AS) or radiation treatment (IR) or As2O3 + radiation treatment (AS + IR). *, P < 0.05, significant difference as compared with the no-treatment group; **, P < 0.05, significant difference as compared with As2O3 or radiation treatment alone.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    As2O3 and radiation treatment significantly inhibit tumor angiogenesis and tumor metastasis. A and B, paraffin-embedded tumor sections (OSCC-3, A; and UM-SCC-74A, B) were stained for tumor blood vessels using anti-human Von Willebrand factor antibodies. Representative photomicrographs of (1) no-treatment (NT), (2) As2O3 2 mg/kg (AS 2 mg/kg), (3) As2O3 5 mg/kg (AS 5 mg/kg), (4) radiation treatment (IR), (5) As2O3 2 mg/kg + radiation treatment (AS 2 mg/kg + IR), and (6) As2O3 5 mg/kg + radiation treatment (AS 5 mg/kg + IR). Microvessel density in the tumor samples was calculated by counting six random fields (×20). C and D, five paraffin-embedded (lungs) step sections of 5 μm with 100-μm spaces were cut and stained with H&E. The number of metastasis nodules present in these sections (OSCC-3, C; and UM-SCC-74A, D) was counted under the microscope. The treatment groups are the same as those described above (A and B). *, P < 0.05, significant difference as compared with the no-treatment group; **, P < 0.05, significant difference in AS + IR groups as compared with AS or IR alone.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    As2O3 treatment protects bone from radiation-induced bone loss. The bone ossicles were fixed in aqueous buffered zinc formalin and analyzed by microcomputed tomography for the bone mineral density. A, representative microcomputed tomography photomicrographs of no-treatment (NT), As2O3 2 mg/kg (AS 2 mg/kg), As2O3 5 mg/kg (AS 5 mg/kg), radiation treatment (IR), As2O3 2 mg/kg + radiation treatment (AS 2 mg/kg + IR), and As2O3 5 mg/kg + radiation treatment (AS 5 mg/kg + IR). B, bone mineral density data are expressed as mg/cc. *, P < 0.05, significant difference as compared with the no-treatment group; **, P < 0.05, significant difference in the AS + IR group as compared with IR alone.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (7)
July 2008
Volume 7, Issue 7
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
Pawan Kumar, Qinghong Gao, Yu Ning, Zhuo Wang, Paul H. Krebsbach and Peter J. Polverini
Mol Cancer Ther July 1 2008 (7) (7) 2060-2069; DOI: 10.1158/1535-7163.MCT-08-0287

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
Pawan Kumar, Qinghong Gao, Yu Ning, Zhuo Wang, Paul H. Krebsbach and Peter J. Polverini
Mol Cancer Ther July 1 2008 (7) (7) 2060-2069; DOI: 10.1158/1535-7163.MCT-08-0287
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
  • Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement